Trial Outcomes & Findings for Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery (NCT NCT04117074)
NCT ID: NCT04117074
Last Updated: 2026-05-19
Results Overview
Pain intensity was measured using the Visual Analog Scale (VAS), a 0-10 scale where 0 indicates no pain and 10 indicates worst pain imaginable. VAS scores were assessed hourly from 0 to 48 hours postoperatively. The area under the curve (AUC) was calculated as the sum of hourly VAS scores over 48 hours, yielding a possible range of 0 to 480. Higher scores indicate greater cumulative pain burden and worse outcomes.
COMPLETED
PHASE3
106 participants
0 to 48 hours postoperatively
2026-05-19
Participant Flow
Patients were recruited from the gynecologic oncology service at a single academic medical center. Potentially eligible participants undergoing planned midline laparotomy will be identified through surgical schedules and clinic visits. Patients will be approached preoperatively by study personnel, and informed consent will be obtained prior to enrollment.
Participant milestones
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Overall Study
STARTED
|
54
|
52
|
|
Overall Study
COMPLETED
|
49
|
50
|
|
Overall Study
NOT COMPLETED
|
5
|
2
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
Baseline characteristics by cohort
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
Total
n=99 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Race (NIH/OMB)
Unknown or Not Reported
|
2 Participants
n=30 Participants
|
1 Participants
n=30 Participants
|
3 Participants
n=60 Participants
|
|
Age, Continuous
|
53.69 Years
STANDARD_DEVIATION 14.40 • n=30 Participants
|
59.78 Years
STANDARD_DEVIATION 12.38 • n=30 Participants
|
56.77 Years
STANDARD_DEVIATION 13.70 • n=60 Participants
|
|
Sex: Female, Male
Female
|
49 Participants
n=30 Participants
|
50 Participants
n=30 Participants
|
99 Participants
n=60 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Asian
|
2 Participants
n=30 Participants
|
3 Participants
n=30 Participants
|
5 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
|
Race (NIH/OMB)
Black or African American
|
8 Participants
n=30 Participants
|
9 Participants
n=30 Participants
|
17 Participants
n=60 Participants
|
|
Race (NIH/OMB)
White
|
37 Participants
n=30 Participants
|
37 Participants
n=30 Participants
|
74 Participants
n=60 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=30 Participants
|
0 Participants
n=30 Participants
|
0 Participants
n=60 Participants
|
PRIMARY outcome
Timeframe: 0 to 48 hours postoperativelyPain intensity was measured using the Visual Analog Scale (VAS), a 0-10 scale where 0 indicates no pain and 10 indicates worst pain imaginable. VAS scores were assessed hourly from 0 to 48 hours postoperatively. The area under the curve (AUC) was calculated as the sum of hourly VAS scores over 48 hours, yielding a possible range of 0 to 480. Higher scores indicate greater cumulative pain burden and worse outcomes.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Analgesia Assessed by the Area Under the Curve of Visual Analog Scale Pain Intensity Scores
|
87.1 VAS score x Hours
Standard Deviation 65.4
|
92.8 VAS score x Hours
Standard Deviation 69.6
|
PRIMARY outcome
Timeframe: 0 to 48 hours postoperativelyTotal opioid consumption in IV mg morphine equivalents from 0 to 48 hours postoperatively will be compared between the two arms.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Total Opioid Consumption
|
21.2 Morphine Miligram Equivalents
Interval 9.3 to 44.3
|
18.8 Morphine Miligram Equivalents
Interval 5.8 to 49.5
|
SECONDARY outcome
Timeframe: Days 1 through 7 post-interventionPopulation: Although 49 participants were assigned to arm A, one participant withdrew immediately after surgery and did not provide any QOR-15 data.
Mean patient-perceived quality of recovery scores using the Quality of Recovery-15 instrument (QoR-15) on postoperative days 1 to 7 were compared between the two arms. The QoR-15 is a validated instrument designed to measure the major domains of postoperative recovery with a score range of 0 indicating the poorest patient-perceived quality of recovery to 150 indicating the highest patient-perceived quality of recovery. QoR-15 scores were analyzed using a linear mixed-effects model for repeated measures across postoperative days 1-7. The single value reported for each arm represents the model-based estimated marginal mean (least squares mean) across all assessed postoperative days using all available observed data without imputation. This reflects an overall POD1-7 summary rather than a score from a single postoperative day.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=48 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Patient-perceived Quality of Recovery as Assessed by the Quality of Recovery-15 Instrument (QoR-15)
|
106.24 Score on scale
95% Confidence Interval 3.03 • Interval 100.24 to 112.24
|
107.46 Score on scale
95% Confidence Interval 2.96 • Interval 101.61 to 113.32
|
SECONDARY outcome
Timeframe: Up to 7 days post-interventionTime to ROBF is defined as the time lapse from the day of surgery (DOS) to the day oral intake is consistently tolerated for 48 hours without vomiting.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Time (Days) to Return of Bowel Function (ROBF)
|
2 days
Interval 2.0 to 3.0
|
3 days
Interval 2.0 to 4.0
|
SECONDARY outcome
Timeframe: Up to 7 days post-interventionIleus is defined as the occurrence of postoperative nausea and vomiting requiring cessation of oral intake and initiation of intravenous hydration +/- nasogastric tube placement following documented ROBF or the persistence of these symptoms beyond postoperative day 5 in the absence of ROBF.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Number of Participants With Postoperative Ileus
|
6 Participants
|
6 Participants
|
SECONDARY outcome
Timeframe: Up to 7 days post-interventionThe Johns Hopkins Highest Level of Mobility (JH-HLM) scale is an ordinal scale ranging from 1 to 8, with higher scores indicating better mobility. Scores represent observed mobility milestones achieved by the patient; a score of 1 indicates lying in bed, while a score of 8 indicates walking 250 feet or more. Mobility was analyzed using a linear mixed-effects model for repeated measures across postoperative days 1-7. The single value reported for each arm represents the model-based estimated marginal mean (least squares mean) across all assessed postoperative days using all available observed data without imputation. This reflects an overall POD1-7 summary rather than a single postoperative day.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Mobility as Assessed by the Johns Hopkins Highest Level of Mobility (JH-HLM) Scale
|
7.25 Score on a scale
Interval 6.8 to 7.71
|
7.27 Score on a scale
Interval 6.82 to 7.72
|
SECONDARY outcome
Timeframe: Up to 7 days post-interventionPopulation: The number of participants with a sedation score ≥2 at any time from postoperative day 0 through postoperative day 7 was reported.
The Pasero Opioid-induced Sedation Scale (POSS) is a valid, reliable tool used to assess sedation when administering opioid medications to manage pain. It uses an ordinal scale of 1-4 with a POSS of 1 or 2 indicating an acceptable level of sedation and a score of 3 or 4 indicating over-sedation and the need for intervention, such as the administration of a reversal agent in the case of a score of 4.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Number of Participants With Sedation Score ≥2 as Assessed by the Pasero Opioid-Induced Sedation Scale
|
1 Participants
0
|
3 Participants
0
|
SECONDARY outcome
Timeframe: Up to 1 yearThe duration of the index inpatient postoperative admission in days.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Length of Stay
|
4 Days
Interval 3.0 to 6.0
|
4.5 Days
Interval 3.0 to 6.0
|
SECONDARY outcome
Timeframe: Arrival in recovery through hospital discharge, up to 1 yearTime to diuresis is defined as the recovery time in hours to achieve a net negative fluid balance sustained over a 24 hour time period.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Time to Postoperative Diuresis
|
48 Hours
Interval 24.0 to 48.0
|
41.75 Hours
Interval 36.0 to 48.0
|
SECONDARY outcome
Timeframe: Arrival in recovery through hospital discharge, up to 1 yearTotal intravenous fluids administered in mL.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Total Intravenous Fluids Administered in mL
|
2523 Milliliters
Interval 1100.0 to 3862.0
|
2379 Milliliters
Interval 884.0 to 4944.0
|
SECONDARY outcome
Timeframe: Start of operation through hospital discharge, up to 1 yearTotal amount (micrograms) of Levophed required.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Amount of Vasopressor Required
|
540 Micrograms
Interval 390.0 to 1100.0
|
890 Micrograms
Interval 620.0 to 1650.0
|
SECONDARY outcome
Timeframe: Start of operation through hospital discharge, up to 1 yearPopulation: The analysis population includes only participants who received vasopressors. Participants who did not receive vasopressors were excluded from this analysis.
Duration (minutes) of vasopressor administration.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=36 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=35 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Duration of Vasopressor Administration
|
139.5 Minutes
Interval 65.25 to 333.75
|
219 Minutes
Interval 60.0 to 321.5
|
SECONDARY outcome
Timeframe: Day of admission through postoperative day 30Population: The denominator reflects the number of participants with available data for this outcome. Participants with missing postoperative complication data were not included in the analysis. In addition, for 30-day outcomes, participants who remained hospitalized at day 30 were not included because these post-discharge outcomes were not applicable.
Number of participants with postoperative complications (Maryland Hospital Acquired Conditions).
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Number Participants With Postoperative Complications
Unscheduled clinic visits
|
1 Participants
|
0 Participants
|
|
Number Participants With Postoperative Complications
Emergency Room visits
|
1 Participants
|
5 Participants
|
|
Number Participants With Postoperative Complications
Outpatient narcotic refills
|
1 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: Up to 1 yearPopulation: Participants with collected data.
Total Direct Cost (Pharmacy and equipment costs, professional fees and the dollar-value of total OR time required for administration of each intervention)
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=45 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Total Direct Cost of TEA Placement and LB Surgical Site Infiltration
|
1168.6 U.S. Dollars
Interval 868.6 to 1334.6
|
670.5 U.S. Dollars
Interval 604.3 to 725.7
|
SECONDARY outcome
Timeframe: Postoperative day 14Population: Participants with collected data.
Patient reported total outpatient narcotic use in IV morphine (mg) equivalents on nurse phone survey administered on postoperative day 14.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=45 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=43 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Post-discharge Narcotic Utilization
|
22.5 PO Morphine Milligram Equivalents
Interval 0.0 to 75.0
|
7.5 PO Morphine Milligram Equivalents
Interval 0.0 to 46.25
|
SECONDARY outcome
Timeframe: Up to 30 days post discharge from index admissionPopulation: Participants with data collected.
Number of participants with 30-day hospital readmission assessed as the number of participants who get readmitted within 30 days of discharge from the initial admission.
Outcome measures
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=47 Participants
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=49 Participants
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Number of Participants With 30-day Hospital Readmission
|
3 Participants
|
6 Participants
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Serum ACTH level in pg/mL.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7ADH level in pg/mL.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7ANP level in pg/mL.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7TNF-α level in pg/mL.
Outcome measures
Outcome data not reported
OTHER_PRE_SPECIFIED outcome
Timeframe: Baseline and postoperative day 7Outcome measures
Outcome data not reported
Adverse Events
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
Arm 1: Thoracic Epidural Analgesia With Bupivicaine
n=49 participants at risk
Thoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Thoracic epidural analgesia (bupivacaine): Perioperative bupivacaine based thoracic epidural placed preoperatively.
|
Arm 2: Surgical Site Infiltration With Liposomal Bupivacaine
n=50 participants at risk
Liposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Liposomal bupivacaine: Surgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
|
|---|---|---|
|
Cardiac disorders
Hypotension
|
34.7%
17/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
32.0%
16/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
|
Gastrointestinal disorders
Nausea/Vomiting
|
20.4%
10/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
28.0%
14/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
|
Cardiac disorders
Hypertension
|
8.2%
4/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
8.0%
4/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
|
Cardiac disorders
Palpitations
|
8.2%
4/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
8.0%
4/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
|
Nervous system disorders
Sedation
|
2.0%
1/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
10.0%
5/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
|
Hepatobiliary disorders
Hepatitis
|
6.1%
3/49 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
10.0%
5/50 • Adverse events were assessed on the day of surgery (postoperative day 0).
Adverse events were assessed in the completed study population (n=99); therefore, all AE tables use the same number of participants at risk.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place